Acceleron Pharma (XLRN) Tops Q2 EPS by 23c, Revenues Beat

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/9/2026

1. HUM
2. SPCX
3. ALHC
4. T
5. PEP
6. CVS
7. UNH
8. AXP
9. ZETA
10. DAL

Go back to Acceleron Pharma (XLRN) Tops Q2 EPS by 23c, Revenues Beat

Acceleron Reports Second Quarter 2020 Operating and Financial Results

August 6, 2020 4:01 PM EDT

- Acceleron recognized approximately $11.1 million in royalty revenue for Q2 2020 from approximately $55.0 million in net U.S. sales of REBLOZYL® (luspatercept-aamt) and a $25.0 million regulatory-based milestone from Bristol Myers Squibb -

- REBLOZYL, the first and only erythroid maturation agent, was approved by the European Commission (EC) to treat transfusion-dependent anemia in adults with myelodysplastic syndromes (MDS) or beta-thalassemia -

- PULSAR Phase 2 topline results presented at the American Thoracic Society (ATS) 2020 Virtual Conference -

- Acceleron plans to host an investor and... More